Sulfasalazine: Difference between revisions
(Blanked the page) |
No edit summary |
||
Line 1: | Line 1: | ||
{{DrugProjectFormSinglePage | |||
|authorTag={{SG}} | |||
|genericName=Sulfasalazine | |||
|aOrAn=a | |||
|drugClass=Sulfonamide | |||
|indicationType=treatment | |||
|indication=mild to moderate ulcerative colitis, rheumatoid arthritis and for pediatric patients with polyarticular-course 1 juvenile rheumatoid arthritis. | |||
|blackBoxWarningTitle=<b><span style="color:#FF0000;">TITLE</span></b> | |||
|blackBoxWarningBody=<i><span style="color:#FF0000;">Condition Name:</span></i> (Content) | |||
|fdaLIADAdult=====Ulcerative Colitis==== | |||
The dosage of AZULFIDINE EN-tabs Tablets should be adjusted to each individual's response and tolerance. | |||
Patients should be instructed to take AZULFIDINE EN-tabs in evenly divided doses, preferably after meals, and to swallow the tablets whole. | |||
=====Initial Therapy===== | |||
*3 to 4 g daily in evenly divided doses with dosage intervals not exceeding eight hours. | |||
*It may be advisable to initiate therapy with a lower dosage, e.g., 1 to 2 g daily, to reduce possible gastrointestinal intolerance. | |||
*If daily doses exceeding 4 g are required to achieve the desired therapeutic effect, the increased risk of toxicity should be kept in mind. | |||
=====Maintenance Therapy===== | |||
*2 g daily | |||
====Rheumatoid Arthritis==== | |||
*2 g daily in two evenly divided doses. | |||
*It is advisable to initiate therapy with a lower dosage of AZULFIDINE EN-tabs, e.g., 0.5 to 1.0 g daily, to reduce possible gastrointestinal intolerance. | |||
*Careful monitoring is recommended for doses over 2 g per day. | |||
|offLabelAdultGuideSupport=There is limited information regarding <i>Off-Label Guideline-Supported Use</i> of Sulfasalazine in adult patients. | |||
|offLabelAdultNoGuideSupport=There is limited information regarding <i>Off-Label Non–Guideline-Supported Use</i> of Sulfasalazine in adult patients. | |||
|fdaLIADPed=====Ulcerative Colitis==== | |||
The dosage of AZULFIDINE EN-tabs Tablets should be adjusted to each individual's response and tolerance. | |||
Patients should be instructed to take AZULFIDINE EN-tabs in evenly divided doses, preferably after meals, and to swallow the tablets whole. | |||
=====Initial Therapy===== | |||
'''*Six years of age and older:''' | |||
*40 to 60 mg/kg of body weight in each 24-hour period, divided into 3 to 6 doses. | |||
=====Maintenance Therapy===== | |||
'''Six years of age and older:''' | |||
*30 mg/kg of body weight in each 24-hour period, divided into 4 doses. | |||
====Juvenile Rheumatoid Arthritis, Polyarticular-Course==== | |||
'''Six years of age and older:''' | |||
*30 to 50 mg/kg of body weight daily in two evenly divided doses. | |||
*Maximum dose is 2 g per day. | |||
*To reduce possible gastrointestinal intolerance, begin with a quarter to a third of the planned maintenance dose and increase weekly until reaching the maintenance dose at one month. | |||
|offLabelPedGuideSupport=There is limited information regarding <i>Off-Label Guideline-Supported Use</i> of Sulfasalazine in pediatric patients. | |||
|offLabelPedNoGuideSupport=There is limited information regarding <i>Off-Label Non–Guideline-Supported Use</i> of Sulfasalazine in pediatric patients. | |||
|alcohol=Alcohol-Sulfasalazine interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication. | |||
}} |
Revision as of 19:04, 9 January 2015
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Stefano Giannoni [2]
Disclaimer
WikiDoc MAKES NO GUARANTEE OF VALIDITY. WikiDoc is not a professional health care provider, nor is it a suitable replacement for a licensed healthcare provider. WikiDoc is intended to be an educational tool, not a tool for any form of healthcare delivery. The educational content on WikiDoc drug pages is based upon the FDA package insert, National Library of Medicine content and practice guidelines / consensus statements. WikiDoc does not promote the administration of any medication or device that is not consistent with its labeling. Please read our full disclaimer here.
Overview
Sulfasalazine is a Sulfonamide that is FDA approved for the treatment of mild to moderate ulcerative colitis, rheumatoid arthritis and for pediatric patients with polyarticular-course 1 juvenile rheumatoid arthritis.. Common adverse reactions include {{{adverseReactions}}}.
Adult Indications and Dosage
FDA-Labeled Indications and Dosage (Adult)
Ulcerative Colitis
The dosage of AZULFIDINE EN-tabs Tablets should be adjusted to each individual's response and tolerance. Patients should be instructed to take AZULFIDINE EN-tabs in evenly divided doses, preferably after meals, and to swallow the tablets whole.
Initial Therapy
- 3 to 4 g daily in evenly divided doses with dosage intervals not exceeding eight hours.
- It may be advisable to initiate therapy with a lower dosage, e.g., 1 to 2 g daily, to reduce possible gastrointestinal intolerance.
- If daily doses exceeding 4 g are required to achieve the desired therapeutic effect, the increased risk of toxicity should be kept in mind.
Maintenance Therapy
- 2 g daily
Rheumatoid Arthritis
- 2 g daily in two evenly divided doses.
- It is advisable to initiate therapy with a lower dosage of AZULFIDINE EN-tabs, e.g., 0.5 to 1.0 g daily, to reduce possible gastrointestinal intolerance.
- Careful monitoring is recommended for doses over 2 g per day.
Off-Label Use and Dosage (Adult)
Guideline-Supported Use
There is limited information regarding Off-Label Guideline-Supported Use of Sulfasalazine in adult patients.
Non–Guideline-Supported Use
There is limited information regarding Off-Label Non–Guideline-Supported Use of Sulfasalazine in adult patients.
Pediatric Indications and Dosage
FDA-Labeled Indications and Dosage (Pediatric)
Ulcerative Colitis
The dosage of AZULFIDINE EN-tabs Tablets should be adjusted to each individual's response and tolerance. Patients should be instructed to take AZULFIDINE EN-tabs in evenly divided doses, preferably after meals, and to swallow the tablets whole.
Initial Therapy
*Six years of age and older:
- 40 to 60 mg/kg of body weight in each 24-hour period, divided into 3 to 6 doses.
Maintenance Therapy
Six years of age and older:
- 30 mg/kg of body weight in each 24-hour period, divided into 4 doses.
Juvenile Rheumatoid Arthritis, Polyarticular-Course
Six years of age and older:
- 30 to 50 mg/kg of body weight daily in two evenly divided doses.
- Maximum dose is 2 g per day.
- To reduce possible gastrointestinal intolerance, begin with a quarter to a third of the planned maintenance dose and increase weekly until reaching the maintenance dose at one month.
Off-Label Use and Dosage (Pediatric)
Guideline-Supported Use
There is limited information regarding Off-Label Guideline-Supported Use of Sulfasalazine in pediatric patients.
Non–Guideline-Supported Use
There is limited information regarding Off-Label Non–Guideline-Supported Use of Sulfasalazine in pediatric patients.
Contraindications
There is limited information regarding Sulfasalazine Contraindications in the drug label.
Warnings
There is limited information regarding Sulfasalazine Warnings' in the drug label.
Adverse Reactions
Clinical Trials Experience
There is limited information regarding Sulfasalazine Clinical Trials Experience in the drug label.
Postmarketing Experience
There is limited information regarding Sulfasalazine Postmarketing Experience in the drug label.
Drug Interactions
There is limited information regarding Sulfasalazine Drug Interactions in the drug label.
Use in Specific Populations
Pregnancy
Pregnancy Category (FDA):
There is no FDA guidance on usage of Sulfasalazine in women who are pregnant.
Pregnancy Category (AUS):
There is no Australian Drug Evaluation Committee (ADEC) guidance on usage of Sulfasalazine in women who are pregnant.
Labor and Delivery
There is no FDA guidance on use of Sulfasalazine during labor and delivery.
Nursing Mothers
There is no FDA guidance on the use of Sulfasalazine in women who are nursing.
Pediatric Use
There is no FDA guidance on the use of Sulfasalazine in pediatric settings.
Geriatic Use
There is no FDA guidance on the use of Sulfasalazine in geriatric settings.
Gender
There is no FDA guidance on the use of Sulfasalazine with respect to specific gender populations.
Race
There is no FDA guidance on the use of Sulfasalazine with respect to specific racial populations.
Renal Impairment
There is no FDA guidance on the use of Sulfasalazine in patients with renal impairment.
Hepatic Impairment
There is no FDA guidance on the use of Sulfasalazine in patients with hepatic impairment.
Females of Reproductive Potential and Males
There is no FDA guidance on the use of Sulfasalazine in women of reproductive potentials and males.
Immunocompromised Patients
There is no FDA guidance one the use of Sulfasalazine in patients who are immunocompromised.
Administration and Monitoring
Administration
There is limited information regarding Sulfasalazine Administration in the drug label.
Monitoring
There is limited information regarding Sulfasalazine Monitoring in the drug label.
IV Compatibility
There is limited information regarding the compatibility of Sulfasalazine and IV administrations.
Overdosage
There is limited information regarding Sulfasalazine overdosage. If you suspect drug poisoning or overdose, please contact the National Poison Help hotline (1-800-222-1222) immediately.
Pharmacology
There is limited information regarding Sulfasalazine Pharmacology in the drug label.
Mechanism of Action
There is limited information regarding Sulfasalazine Mechanism of Action in the drug label.
Structure
There is limited information regarding Sulfasalazine Structure in the drug label.
Pharmacodynamics
There is limited information regarding Sulfasalazine Pharmacodynamics in the drug label.
Pharmacokinetics
There is limited information regarding Sulfasalazine Pharmacokinetics in the drug label.
Nonclinical Toxicology
There is limited information regarding Sulfasalazine Nonclinical Toxicology in the drug label.
Clinical Studies
There is limited information regarding Sulfasalazine Clinical Studies in the drug label.
How Supplied
There is limited information regarding Sulfasalazine How Supplied in the drug label.
Storage
There is limited information regarding Sulfasalazine Storage in the drug label.
Images
Drug Images
{{#ask: Page Name::Sulfasalazine |?Pill Name |?Drug Name |?Pill Ingred |?Pill Imprint |?Pill Dosage |?Pill Color |?Pill Shape |?Pill Size (mm) |?Pill Scoring |?NDC |?Drug Author |format=template |template=DrugPageImages |mainlabel=- |sort=Pill Name }}
Package and Label Display Panel
{{#ask: Label Page::Sulfasalazine |?Label Name |format=template |template=DrugLabelImages |mainlabel=- |sort=Label Page }}
Patient Counseling Information
There is limited information regarding Sulfasalazine Patient Counseling Information in the drug label.
Precautions with Alcohol
Alcohol-Sulfasalazine interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication.
Brand Names
There is limited information regarding Sulfasalazine Brand Names in the drug label.
Look-Alike Drug Names
There is limited information regarding Sulfasalazine Look-Alike Drug Names in the drug label.
Drug Shortage Status
Price
References
The contents of this FDA label are provided by the National Library of Medicine.